Saxby Pridmore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saxby Pridmore has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Jamshid Ahmadi
Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
15 shared publications - William Pridmore
Hobart, Tas
15 shared publications Yvonne Turnier-Shea
Hobart TMS
14 shared publicationsMarzena Rybak
Hobart TMS
11 shared publications- Garry Walter
Discipline of Psychiatry, University of Sydney, and Child and Adolescent Mental Health Services, Northern Sydney Local Health District, Sydney, NSW, Australia
8 shared publications Garry Walter
Discipline of Psychiatry, University of Sydney, Child and Adolescent Mental Health Services, Northern Sydney Local Health District, North Ryde, NSW, Australia
7 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by SAGE Publications in Australasian Psychiatry
Letter to editor: Four patients receive long-term weekly maintenance TMS
- 20 September 2026
- Published by SAGE Publications in Australasian Psychiatry
Open AccessLetter to editor: Four patients receive long-term weekly maintenance TMS
- Open Access
- 11 June 2026
- Published by SAGE Publications in Australasian Psychiatry
Transcranial magnetic stimulation (TMS) and veteran status
- 11 June 2026
- Published by SAGE Publications in Australasian Psychiatry
Open AccessTranscranial magnetic stimulation (TMS) and veteran status
- Open Access
- 26 February 2026
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 34 (4) , 325-327
Reconsideration of the lifetime limit of 50 rebated TMS sessions
Objective: To make a case for the Medicare benefits schedule (MBS) rule, that depressed patients who benefit from transcranial magnetic stimulation (TMS) have a lifetime limit of 50 treatments, to be reconsidered. Conclusion: Evidence proves TMS can produce remission in major depressive disorder/treatment resistant disorder (MDD/TRD) when medication has failed. This is a relapsing disorder, and further treatments are usually required (but are prevented by this limit). We suggest the limit be raised to 70 treatments (2 courses, or similar) per year.
- 26 February 2026
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 34 (4) , 325-327
Open AccessReconsideration of the lifetime limit of 50 rebated TMS sessions
Objective: To make a case for the Medicare benefits schedule (MBS) rule, that depressed patients who benefit from transcranial magnetic stimulation (TMS) have a lifetime limit of 50 treatments, to be reconsidered. Conclusion: Evidence proves TMS can produce remission in major depressive disorder/treatment resistant disorder (MDD/TRD) when medication has failed. This is a relapsing disorder, and further treatments are usually required (but are prevented by this limit). We suggest the limit be raised to 70 treatments (2 courses, or similar) per year.
- Open Access
- 30 October 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 34 (1) , 17-19
TMS is needed in Public Mental Health Services
Transcranial magnetic stimulation (TMS) is essential for the comprehensive treatment of major depressive disorder (MDD). Around Australia, it is widely available in private practice, but in few Public Mental Health Services. TMS is a revolutionary treatment. Using electromagnetic apparatus, the function of precise local and distant regions of the brain can be modulated, with minimal side effects. Half of patients with MDD do not respond to antidepressant medication. However, a large proportion of medication non-responders can be brought to remission using TMS. This intervention is cost-effective and availability in public practice should be increased.
- 30 October 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 34 (1) , 17-19
Open AccessTMS is needed in Public Mental Health Services
Transcranial magnetic stimulation (TMS) is essential for the comprehensive treatment of major depressive disorder (MDD). Around Australia, it is widely available in private practice, but in few Public Mental Health Services. TMS is a revolutionary treatment. Using electromagnetic apparatus, the function of precise local and distant regions of the brain can be modulated, with minimal side effects. Half of patients with MDD do not respond to antidepressant medication. However, a large proportion of medication non-responders can be brought to remission using TMS. This intervention is cost-effective and availability in public practice should be increased.
- Open Access
- 29 July 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (5) , 855-856
Open letter to the Medical Services Advisory Committee regarding TMS Item Number regulations
Objective: To present the perspective of professionals working in the field of transcranial magnetic stimulation (TMS) regarding the regulations which impact the availability of government subsidisation via Australian Medicare Benefits Schedule Item Number rebates to patients with major depressive disorder (MDD) who are seeking TMS treatment. Conclusions: We argue that three regulations should be withdrawn: (1) that patients who received TMS prior to 1 November 2021 are ineligible for TMS rebates after 1 November 2021; (2) that every person is subject to a limit of 50 TMS treatments in a lifetime; and (3) that rebates are not available for maintenance TMS. We also conclude that consideration should be given to the provision of rebates for TMS treatments when it is delivered as a first-line treatment for MDD.
- 29 July 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (5) , 855-856
Open AccessOpen letter to the Medical Services Advisory Committee regarding TMS Item Number regulations
Objective: To present the perspective of professionals working in the field of transcranial magnetic stimulation (TMS) regarding the regulations which impact the availability of government subsidisation via Australian Medicare Benefits Schedule Item Number rebates to patients with major depressive disorder (MDD) who are seeking TMS treatment. Conclusions: We argue that three regulations should be withdrawn: (1) that patients who received TMS prior to 1 November 2021 are ineligible for TMS rebates after 1 November 2021; (2) that every person is subject to a limit of 50 TMS treatments in a lifetime; and (3) that rebates are not available for maintenance TMS. We also conclude that consideration should be given to the provision of rebates for TMS treatments when it is delivered as a first-line treatment for MDD.
- Open Access
- 20 January 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (3) , 475-480
TMS in major depression: A retrospective naturalistic study including two subjective tools
Objective: To report the outcomes of transcranial magnetic stimulation (TMS) treatment of patients with acute major depressive disorder (MDD), with particular attention to the performance of the individual assessment tools, including two new subjective mood scales. Methods: Patients with MDD were treated with up to 35 daily TMS sessions. Objective quantification of mood utilised the Hamilton Depression Rating Scale (HAM-D6) and the Clinical Global Impression-Severity scale (CGI-S). Subjective quantification was made using the Subjective Depression Scale (SDS6) and a new Daily Emotion Score (DES) – a single question which is asked daily. Results: Ninety consecutive patients (58 females; 64.4%) with a mean age of 46.9 years were included. Using HAM-D6 criteria, 51 patients (56.7%) achieved remission. Scores obtained using the different tools correlated well at the same time point, especially at the conclusion of TMS therapy. The only statistically significant independent predictors of remission were the percentage improvement at session 10 (relative to baseline) in the SDS6 ( p = .0026) and in the DES ( p = .043). Conclusion: The SDS6 was confirmed as a valuable companion for the HAM-D6. The DES correlated with the other subjective tool (SDS6); the latter, in particular, may also have utility in predicting treatment outcome.
- 20 January 2025
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (3) , 475-480
Open AccessTMS in major depression: A retrospective naturalistic study including two subjective tools
Objective: To report the outcomes of transcranial magnetic stimulation (TMS) treatment of patients with acute major depressive disorder (MDD), with particular attention to the performance of the individual assessment tools, including two new subjective mood scales. Methods: Patients with MDD were treated with up to 35 daily TMS sessions. Objective quantification of mood utilised the Hamilton Depression Rating Scale (HAM-D6) and the Clinical Global Impression-Severity scale (CGI-S). Subjective quantification was made using the Subjective Depression Scale (SDS6) and a new Daily Emotion Score (DES) – a single question which is asked daily. Results: Ninety consecutive patients (58 females; 64.4%) with a mean age of 46.9 years were included. Using HAM-D6 criteria, 51 patients (56.7%) achieved remission. Scores obtained using the different tools correlated well at the same time point, especially at the conclusion of TMS therapy. The only statistically significant independent predictors of remission were the percentage improvement at session 10 (relative to baseline) in the SDS6 ( p = .0026) and in the DES ( p = .043). Conclusion: The SDS6 was confirmed as a valuable companion for the HAM-D6. The DES correlated with the other subjective tool (SDS6); the latter, in particular, may also have utility in predicting treatment outcome.
- Open Access
- 17 December 2024
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (2) , 299
A suicide in a Russian novel
- 17 December 2024
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (2) , 299
Open AccessA suicide in a Russian novel
- 13 September 2024
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (1) , 169
Mental State Mental State
- 13 September 2024
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 33 (1) , 169
Mental State Mental State
- 21 May 2024
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 32 (4) , 395
Curing Stubborn Depression: Emerging and Breakthrough Therapies for Treatment-Resistant Depression
- 21 May 2024
- Published by SAGE Publications in Australasian Psychiatry
- Vol. 32 (4) , 395
Curing Stubborn Depression: Emerging and Breakthrough Therapies for Treatment-Resistant Depression
- Open Access
- 24 April 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (5) , 415
A Case Series Study of Weekly or Fortnightly Transcranial Magnetic Stimulation (TMS) in Major Depressive Disorder
Background: Major depressive disorder (MDD) is frequently chronic and relapsing. The use of maintenance or continuation transcranial magnetic stimulation (TMS) has received clinical and some research support. Objective: To conduct a case series study to report the outcomes of once-weekly (OW) or once-fortnightly (OF) continuation TMS in a real-life setting. Methods: We offered OW or OF TMS sessions to patients with MDD in remission or partial remission/relapse. Results: Ten patients received OW TMS and four received OF TMS, for 8 to 46 weeks. No patients in either group who were in remission or partial remission at baseline experienced a relapse. Improvements in HAMD6 and CGI-S scores were statistically significant or of borderline significance for the total sample and the OW group. Conclusions: This naturalistic, open-label observational study indicates that OW TMS is effective as maintenance therapy in MDD, while also offering some support for OF TMS maintenance in preventing relapse.
- 24 April 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (5) , 415
Open AccessA Case Series Study of Weekly or Fortnightly Transcranial Magnetic Stimulation (TMS) in Major Depressive Disorder
Background: Major depressive disorder (MDD) is frequently chronic and relapsing. The use of maintenance or continuation transcranial magnetic stimulation (TMS) has received clinical and some research support. Objective: To conduct a case series study to report the outcomes of once-weekly (OW) or once-fortnightly (OF) continuation TMS in a real-life setting. Methods: We offered OW or OF TMS sessions to patients with MDD in remission or partial remission/relapse. Results: Ten patients received OW TMS and four received OF TMS, for 8 to 46 weeks. No patients in either group who were in remission or partial remission at baseline experienced a relapse. Improvements in HAMD6 and CGI-S scores were statistically significant or of borderline significance for the total sample and the OW group. Conclusions: This naturalistic, open-label observational study indicates that OW TMS is effective as maintenance therapy in MDD, while also offering some support for OF TMS maintenance in preventing relapse.